RAMBALDI, ALESSANDRO
RAMBALDI, ALESSANDRO
Dipartimento di Oncologia ed Emato-Oncologia
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
2024 T. Barbui, A. Carobbio, V. De Stefano, A. Alvarez-Larran, A. Ghirardi, G. Carioli, F. Fenili, E. Rossi, F. Ciceri, M. Bonifacio, A. Iurlo, F. Palandri, G. Benevolo, F. Pane, A. Ricco, G. Carli, M. Caramella, D. Rapezzi, C. Musolino, S. Siragusa, E. Rumi, A. Patriarca, N. Cascavilla, B. Mora, E. Cacciola, L. Calabresi, G.G. Loscocco, P. Guglielmelli, F. Gesullo, S. Betti, F. Ramundo, F. Lunghi, L. Scaffidi, C. Bucelli, D. Cattaneo, N. Vianelli, M. Bellini, M.C. Finazzi, G. Tognoni, A. Rambaldi, A.M. Vannucchi
Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT
2024 C. Gurnari, L. Koster, L. Baaij, M. Heiblig, I. Yakoub-Agha, M. Collin, J. Passweg, C.E. Bulabois, A. Khan, M. Loschi, F. Carnevale-Schianca, E. Crisà, D. Caravelli, J. Kuball, F. Saraceni, A. Olivieri, A. Rambaldi, A.G. Kulasekararaj, P.J. Hayden, M. Badoglio, F. Onida, C. Scheid, F. Franceschini, A. Mekinian, S. Savic, M.T. Voso, J. Drozd-Sokolowska, J.A. Snowden, K. Raj, T. Alexander, M. Robin, R. Greco, D.P. Mclornan
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial
2024 G. Cavallaro, A. Grassi, C. Pavoni, M.C. Micò, A. Busca, I.M. Cavattoni, S. Santarone, C. Borghero, A. Olivieri, G. Milone, P. Chiusolo, P. Musto, R. Saccardi, F. Patriarca, F. Pane, G. Saporiti, P. Rivela, E. Terruzzi, R. Cerretti, G. Marotta, A.M. Carella, A. Nagler, D. Russo, P. Corradini, P. Bernasconi, A.P. Iori, L. Castagna, N. Mordini, E. Oldani, C. Di Grazia, A. Bacigalupo, A. Rambaldi
Molecular prognostication for transplant decision making of patients with myelodysplastic syndromes: A retrospective single-center study
2024 A. Condorelli, M. Frigeni, G. Quaresmini, S. Salmoiraghi, C. Pavoni, A. Grassi, M. Raviglione, A. Civini, A. Putelli, F. Lussana, M.C. Finazzi, A. Algarotti, M.C. Micò, O. Spinelli, A. Rambaldi
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera
2023 T. Barbui, A.M. Vannucchi, V. De Stefano, A. Carobbio, A. Ghirardi, G. Carioli, A. Masciulli, E. Rossi, F. Ciceri, M. Bonifacio, A. Iurlo, F. Palandri, G. Benevolo, F. Pane, A. Ricco, G. Carli, M. Caramella, D. Rapezzi, C. Musolino, S. Siragusa, E. Rumi, A. Patriarca, N. Cascavilla, B. Mora, E. Cacciola, C. Mannarelli, G.G. Loscocco, P. Guglielmelli, F. Gesullo, S. Betti, F. Lunghi, L. Scaffidi, C. Bucelli, N. Vianelli, M. Bellini, M.C. Finazzi, G. Tognoni, A. Rambaldi
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
2023 E. Sauta, M. Robin, M. Bersanelli, E. Travaglino, M. Meggendorfer, L. Zhao, J.C. Caballero Berrocal, C. Sala, G. Maggioni, M. Bernardi, C. Di Grazia, L. Vago, G. Rivoli, L. Borin, S. D'Amico, C.A. Tentori, M. Ubezio, A. Campagna, A. Russo, D. Mannina, L. Lanino, P. Chiusolo, L. Giaccone, M.T. Voso, M. Riva, E.N. Oliva, M. Zampini, E. Riva, O. Nibourel, M. Bicchieri, N. Bolli, A. Rambaldi, F. Passamonti, V. Savevski, A. Santoro, U. Germing, S. Kordasti, V. Santini, M. Diez-Campelo, G. Sanz, F. Sole, W. Kern, U. Platzbecker, L. Ades, P. Fenaux, T. Haferlach, G. Castellani, M.G. Della Porta
Optimal Use of Novel Immunotherapeutics in B-Cell Precursor ALL
2023 F. Lussana, G. Cavallaro, P. De Simone, A. Rambaldi
High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias
2023 A. Magi, G. Mattei, A. Mingrino, C. Caprioli, C. Ronchini, G. Frigè, R. Semeraro, D. Bolognini, A. Rambaldi, A. Candoni, E. Colombo, L. Mazzarella, P.G. Pelicci
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
2022 M.Y. Konopleva, C. Röllig, J. Cavenagh, D. Deeren, L. Girshova, J. Krauter, G. Martinelli, P. Montesinos, J.A. Schäfer, O. Ottmann, M. Petrini, A. Pigneux, A. Rambaldi, C. Recher, R. Rodriguez-Veiga, D. Taussig, N. Vey, S. Yoon, M. Ott, S. Muehlbauer, B.M. Beckermann, O. Catalani, M. Genevray, K. Mundt, C. Jamois, P. Fenaux, A.H. Wei
Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1-JAK2 positive myeloid sarcoma and acute B-lymphoblastic leukemia
2022 G. Rizzuto, M. Leoncin, S. Imbergamo, D. Taurino, M.C. Mico, M. Tosi, A. Michelato, K. Buklijas, O. Spinelli, F. Lussana, F. Lessi, M. Pizzi, L. Bonaldi, G. Binotto, A. Rambaldi, C. Gurrieri
Isatuximab monotherapy in patients with refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma: Phase 2 study
2022 N. Boissel, P. Chevallier, V. Doronin, L. Griskevicius, A. Maschan, J. Mccloskey, A. Rambaldi, G. Rossi, A. Sokolov, U. Wartiovaara-Kautto, C. Oprea, G. Abbadessa, A. Gosselin, S. Macé, X. Thomas
Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT
2022 J.-. Hernandez-Boluda, A. Pereira, N. Zinger, L. Gras, R. Martino, S. Paneesha, J. Finke, A. Chinea, A. Rambaldi, M. Robin, R. Saccardi, A. Natale, J.A. Snowden, P. Tsirigotis, C. Vallejo, G. Wulf, B. Xicoy, D. Russo, J. Maertens, E. Daguindau, S. Lenhoff, P. Hayden, T. Czerw, D.P. Mclornan, I. Yakoub-Agha
Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study
2022 A. Candoni, D. Lazzarotto, A. Rambaldi, M.V. Dubbini, P. Bresciani, A. Busca, W. Arcese, A.P. Iori, R. Sorasio, G. Irrera, R. Fanin, F. Ciceri, F. Bonifazi
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
2022 T. Barbui, A. Ghirardi, A. Carobbio, A. Masciulli, G. Carioli, A. Rambaldi, M.C. Finazzi, M. Bellini, E. Rumi, D. Vanni, O. Borsani, F. Passamonti, B. Mora, M. Brociner, P. Guglielmelli, C. Paoli, A. Alvarez-Larran, A. Triguero, M. Garrote, H. Pettersson, B. Andréasson, G. Barosi, A.M. Vannucchi
Breakthrough infections in MPN-COVID vaccinated patients
2022 T. Barbui, A. Carobbio, A. Ghirardi, A. Iurlo, V. De Stefano, M.A. Sobas, E. Rumi, E.M. Elli, F. Lunghi, M. Gasior Kabat, B. Cuevas, P. Guglielmelli, M. Bonifacio, M. Marchetti, A. Alvarez-Larran, L. Fox, M. Bellini, R. Daffini, G. Benevolo, G. Carreno-Tarragona, A. Patriarca, H.K. Al-Ali, M.M.M. Andrade-Campos, F. Palandri, C. Harrison, M.A. Foncillas, S. Osorio, S. Koschmieder, E. Magro Mazo, J. Kiladjian, E. Bolaños Calderón, F.H. Heidel, K. Quiroz Cervantes, M. Griesshammer, V. Garcia-Gutierrez, A.M. Sanchez, J.C. Hernandez-Boluda, E. Lopez Abadia, G. Carli, M. Sagues Serrano, R. Kusec, B. Xicoy Cirici, M. Guenova, B. Navas Elorza, A. Angona, E. Cichocka, A. Kulikowska de Nałęcz, D. Cattaneo, C. Bucelli, S. Betti, O. Borsani, F. Cavalca, S. Carbonell, N. Curto-Garcia, L. Benajiba, A. Rambaldi, A.M. Vannucchi
Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use: GMP-compliant polyclonal T cell expansion in G-Rex
2022 E. Gotti, S. Tettamanti, S. Zaninelli, C. Cuofano, I. Cattaneo, M.C. Rotiroti, S. Cribioli, R. Alzani, A. Rambaldi, M. Introna, J. Golay
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19
2022 T. Barbui, A. Carobbio, A. Ghirardi, A. Iurlo, M.A. Sobas, E.M. Elli, E. Rumi, V. De Stefano, F. Lunghi, M. Marchetti, R. Daffini, M. Gasior Kabat, B. Cuevas, M.L. Fox, M.M. Andrade-Campos, F. Palandri, P. Guglielmelli, G. Benevolo, C. Harrison, M. Foncillas, M. Bonifacio, A. Alvarez-Larran, J. Kiladjian, E. Bolaños Calderón, A. Patriarca, K. Quiroz Cervantes, M. Griesshammer, V. Garcia-Gutierrez, A. Marin Sanchez, E. Magro Mazo, G. Carli, J.C. Hernandez-Boluda, S. Osorio, G. Carreno-Tarragona, M. Sagues Serrano, R. Kusec, B. Navas Elorza, A. Angona, B. Xicoy Cirici, E. Lopez Abadia, S. Koschmieder, D. Cattaneo, C. Bucelli, E. Cichocka, A.K. de Nałęcz, F. Cavalca, O. Borsani, S. Betti, M. Bellini, N. Curto-Garcia, A. Rambaldi, A.M. Vannucchi
Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy
2022 S.K. Khaled, K. Claes, Y.T. Goh, Y.L. Kwong, N. Leung, W. Mendrek, R. Nakamura, J. Sathar, E. Ng, N. Nangia, S. Whitaker, A. Rambaldi
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study
2022 P. Guglielmelli, A. Ghirardi, A. Carobbio, A. Masciulli, C. Maccari, B. Mora, E. Rumi, A. Triguero, M.C. Finazzi, H. Pettersson, C. Paoli, F. Mannelli, D. Vanni, A. Rambaldi, F. Passamonti, A. Alvarez-Larran, B. Andreasson, A.M. Vannucchi, T. Barbui
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01
2022 F. Bonifazi, C. Pavoni, J. Peccatori, F. Giglio, M. Arpinati, A. Busca, P. Bernasconi, A. Grassi, A. Paola Iori, F. Patriarca, L. Brunello, C. Di Grazia, A. Michele Carella, D. Cilloni, A. Picardi, A. Proia, S. Santarone, R. Sorasio, P. Carluccio, P. Chiusolo, A. Cupri, M. Luppi, C. Nozzoli, D. Baronciani, M. Casini, G. Grillo, M. Musso, F. Onida, G. Palazzo, M. Parma, S. Tringali, A. Vacca, D. Vallisa, N. Sacchi, E. Oldani, A. Masciulli, A. Gheorghiu, C. Girmenia, M. Martino, B. Bruno, A. Rambaldi, F. Ciceri